ArticleScientific reports2025
The relationship between acid-sensing ion channel, ASIC2, and oncogenic β-catenin signaling in ovarian cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation associated with incessant ovulation plays a key role in epithelial ovarian cancer (EOC) pathogenesis. Ion channels, such as acid-sensing ion channel-2 or ASIC2 are known to be upregulated in inflammatory conditions and may play a role in cancer cell invasion and metastasis. Previously we reported the role of phosphodiesterase 10A (PDE10) modulation of β-catenin in ovarian cancer, and are currently investigating its contribution to ovarian pathogenesis. Differential ASIC2 expression was noted with PDE10 modulation in both pre-malignant and ovarian cancer tissues. Hence, we presently report the potential role of ASIC2 in EOC development and progression as well as involvement with PDE10. ASIC2 protein is expressed across all EOC cell lines, primarily within the nucleus. Knockout of PDE10 decreased ASIC2. Conversely, ASIC2 inhibition decreased ASIC2 as well as PDE10 protein levels. ASIC2 inhibition via Diminazene also produced marked ovarian cancer death. While changes in extracellular pH did not impact ASIC2 expression, intracellular pH and calcium levels increased with ASIC inhibition. Calcium increases induced a decrease in oncogenic β-catenin. There may be a direct relationship between PDE10 and ASIC2 protein expression in EOC through convergence on a β-catenin mediated signaling pathway. This could potentially implicate ion channels, specifically ASIC2, as a link between the acidic tumor microenvironment and cancer cell signaling. It is also possible that ASIC2 plays a crucial role in acidosis-mediated tumorigenesis in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.